Boehringer Ingelheim’s weekly injection, survodutide, reduced visceral and liver fat in patients with overweight or obesity, but overall weight loss data did not meet what analysts consider competitive benchmarks. The results were presented at the 2026 American Diabetes Association conference on June 8.
Survodutide, a GLP-1/GIP candidate developed in partnership with Zealand Pharma, showed an average weight loss of up to 16.6% in the Phase 3 SYNCHRONIZE-1 study. Placebo participants lost 3.2% of their body weight after 76 weeks. Boehringer said this effect was statistically significant.
Analysts at BMO Capital Markets said in a note to investors that survodutide “demonstrated a less competitive profile vs other agents.” They added, “We think it could be more difficult for Zealand/BI to find a competitive foothold in today’s rapidly evolving obesity/metabolic market.” However, BMO also noted that the placebo group had higher use of prohibited GLP-1s, which may have contributed to greater-than-expected weight loss among controls.
Despite these findings on overall weight reduction, both Boehringer and BMO pointed out specific benefits regarding fat mass. A pre-specified analysis from SYNCHRONIZE-1 indicated patients receiving survodutide lost up to 34% of their visceral fat mass versus baseline and saw liver fat drop by 63.1% after 76 weeks. Boehringer said these results suggest survodutide induces “a targeted reduction in metabolically harmful fat,” and BMO analysts described the figures as “impressive.”
Regarding safety outcomes, Boehringer reported that gastrointestinal side effects led to discontinuation for 19% of patients taking survodutide, compared with 2.9% for those on placebo. According to BMO’s note, this may have been influenced by dosing schedules that did not allow down titration during certain segments of the study.
Additional data from the Phase 3 SYNCHRONIZE-MASLD study showed that at week 48, up to 84.2% of patients treated with survodutide experienced at least a 30% relative decrease in liver fat compared with 24.3% among placebo recipients—a significant treatment effect, according to Boehringer’s release.
